TY  - JOUR
TI  - A retrospective, observational study: early versus late favipiravir 
in COVID-19 pneumonia
AB  - Aim: Positive results have been reported regarding the early use of favipiravir,a RNA-dependent RNA polymerase inhibitor,in the COVID-19 
pandemic. In our study, we aimed to understand the potential role of favipiravir in controlling COVID-19 pneumonia and sepsis by 
comparing the early use of favipiravir with the late using.
Material and Method: Treatments are carried out in line with the guidelines constantly updated by the Ministry of Health in Turkey. 
Following the guide published on April 14,2020,we examined 18 patients who received favipiravir as the last treatment option in the late 
period and 17 patients who received favipiravir in the early period in two different groups.We recorded the demographic characteristics,co
morbidities,APACHE-II scores,consecutive SOFA scores and mortality status of the patients in both groups.
Results: The difference between groups in terms of gender and age was not statistically significant.The difference between groups in terms of 
APACHE-II score was statistically significant.(p=0.018)The late group also had higher APACHE-II scores.The difference between groups in 
terms of exitus was not statistically significant but lower in the group using favipiravir early.
Conclusion: In studies with a limited number of patients, favipiravir has been shown to have a significant advantage over lopinavir/ritonavir 
in viral clearance as well as a significant reduction in viral load when used in the early period.Similarly,in our study,patients who used 
favipiravir in the late period came to us more seriously and the mortality rate was higher. We think that favipiravir had a significant effect 
even in studies with a small number of patients, and larger studies are needed in this area.
AU  - AYYILDIZ, AYŞE
AU  - Çobaner, Nurdan
AU  - YELKEN, BIRGUL BUYUKKIDAN
AU  - Erben, Nurettin
DO  - 10.47582/jompac.1056194
PY  - 2022
JO  - Journal of medicine and palliative care (Online)
VL  - 3
IS  - 1
SN  - 2717-7505
SP  - 22
EP  - 25
DB  - TRDizin
UR  - http://search/yayin/detay/530336
ER  -